Quarterly Results- overall
Annual Results- Scale
Annual Results- Liquidity
Annual Results- Profitability/Return
Annual Results- Valuation
External Ecosystem
Sector
Major Subsidiaries/Associates
Key Clients
Products
Products
Product details
Operations
Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
|
Venus Remedies (NSE:VENUSREM) Q2 FY27 Board Outcome and European Units
Read More
|
|
Venus Remedies Q2 EBITDA margin expands to 19.43% on revenue growth
Read More
|
|
Venus Remedies Q2 FY27 Results: Key Financials Disclosed
Read More
|
|
Venus Remedies Q2 Results FY27: Profit Up 27.42% to Rs 25.65 Cr
Read More
|
|
Below All Moving Averages and Now at Lower Circuit: Venus Remedies Ltd Loses 4.9% in a Single Session
Read More
|
|
Venus Remedies International Drug Approvals and Market Expansion
Read More
|
|
Venus Remedies receives five marketing approvals In Kazakhstan, Peru, Kuwait, Argentina
Read More
|
|
Is Venus Remedies the Best Stock in Its Sector? A Look at the Numbers
Read More
|
|
Venus Remedies (NSE:VENUSREM) Secures Five Global Drug Approvals
Read More
|
|
Venus Remedies secures 5 marketing authorisations in 4 global markets
Read More
|
|
Venus Remedies Upper Circuit Today: Price, Data and Peers
Read More
|
|
Venus Remedies VENUSREM Q2 FY27 Regulation 74(5) Compliance
Read More
|